2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11A.08 Molecular and Immunological Features Associated with Long-Term Benefit in Metastatic NSCLC Patients Undergoing Immune Checkpoint Blockade

P2.11A.08 Molecular and Immunological Features Associated with Long-Term Benefit in Metastatic NSCLC Patients Undergoing Immune Checkpoint Blockade

Back to course

Pdf Summary

The study investigates potential biomarkers for predicting long-term benefits in metastatic non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint blockade (ICB) therapy, a form of immunotherapy. Despite the widespread use of ICB in treating various solid tumors, including NSCLC, identifying a reliable biomarker for sustained treatment benefits remains a challenge faced by the medical community.<br /><br />In this research, 49 patients with metastatic NSCLC were analyzed. They were categorized as long-term responders (LTR), those showing a response to ICB for over 24 months, and short-term responders (STR), those with a response lasting less than six months. Comprehensive data, including longitudinal blood specimens and baseline tumor tissues, were collected and assessed using next-generation sequencing and spatial proteomic profiling.<br /><br />The study found that LTR patients had specific characteristics differing significantly from STR patients. These included a higher prevalence of PD-L1 positive tumors and a greater occurrence of immune-related adverse events (irAEs), suggesting a link to more robust pre-existing antitumor immunity. Furthermore, within the tumor, LTR patients exhibited higher levels of proteins like IDO1, CD8, and PD-L1, whereas STR individuals had elevated expressions of proteins such as B7-H3, CD56, and OX40L.<br /><br />The findings suggest that factors like PD-L1 expression and the presence of irAEs could serve as predictive biomarkers for long-term benefits from ICB treatment, potentially guiding more tailored therapeutic strategies in NSCLC. This research highlights the clinical significance of understanding molecular and immunological features in enhancing the outcomes of immunotherapy in cancer treatment.

Asset Subtitle

Pedro Rocha

Meta Tag

Speaker Pedro Rocha

Topic Metastatic NSCLC – Immunotherapy

Keywords

biomarkers

metastatic NSCLC

immune checkpoint blockade

long-term responders

short-term responders

PD-L1 expression

immune-related adverse events

next-generation sequencing

spatial proteomic profiling

immunotherapy